Cannatrek has announced it will supply medicinal cannabis products to LYPHE Group in support of Project Twenty21, Europe’s first and largest national medical cannabis registry.
By the end of 2021, Project Twenty21 aims to recruit up to 20,000 patients suffering from conditions including anxiety, chronic pain, epilepsy, multiple sclerosis, post-traumatic stress disorder, substance use disorder and Tourette’s Syndrome. It will help them access subsidized medical cannabis while simultaneously gathering evidence of efficacy.
Cannatrek will supply medicinal cannabis flowers for the project via LYPHE Group (Astral Health UK) which will be crushed and inhaled via a vaporizer.
Cannatrek CEO Tommy Huppert said: “For us it opens up international trade pathways in what is still a nascent industry. Project Twenty21, with 20,000 patients, represents a very big study and will produce lots of valuable data for Cannatrek and for the industry.”
He added: “Cannatrek is an important part of the supply chain for this study. Supply chains are being created very rapidly worldwide and we want to be front and centre of them.”
Chief commercial officer at LYPHE Group Chris Ashton said: “Project Twenty21 is an incredibly important study in the UK and presents a great opportunity for the industry to demonstrate with valuable data the effectiveness and safety of using medical cannabis.”
